Monte Rosa Therapeutics (GLUE) Assets Average (2023 - 2025)
Historic Assets Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $409.7 million.
- Monte Rosa Therapeutics' Assets Average rose 2430.74% to $409.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.7 million, marking a year-over-year increase of 2430.74%. This contributed to the annual value of $371.2 million for FY2024, which is N/A changed from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Assets Average stood at $409.7 million, which was up 2430.74% from $376.4 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Assets Average ranged from a high of $416.0 million in Q1 2025 and a low of $265.4 million during Q3 2023
- Moreover, its 3-year median value for Assets Average was $317.5 million (2024), whereas its average is $333.6 million.
- In the last 5 years, Monte Rosa Therapeutics' Assets Average soared by 395.07% in 2024 and then soared by 4582.46% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Assets Average (Quarter) stood at $277.9 million in 2023, then skyrocketed by 35.61% to $376.9 million in 2024, then rose by 8.7% to $409.7 million in 2025.
- Its Assets Average was $409.7 million in Q3 2025, compared to $376.4 million in Q2 2025 and $416.0 million in Q1 2025.